Tisotumab vedotin is currently in clinical development for the treatment of patients with recurrent or metastatic cervical cancer who have received at least one prior systemic therapy. Cervical cancer develops in a woman’s cervix (lower part of the womb). It mainly affects sexually active women aged between 30 and 45 years. Cervical cancer often has no symptoms in its early stages. Cervical cancer that has spread to another part of the body is called advanced or metastatic cancer. Cancer that returns after months or years of the completion of the initial treatment is called recurrent cancer. The most common symptom of cervical cancer includes bleeding from the vagina at times other than the usual periods. Despite the recent developments, the prognosis remains poor and systemic therapy options are needed for women with recurrent and metastatic cervical cancer.
Tisotumab vedotin is administered by intravenous infusion. It is an antibody-drug conjugate that binds to tissue factor (TF), a protein expressed on the cell surface of tumour cells. This then induces cancer cells death. If licenced tisotumab vedotin will offer a treatment option for adult females with recurrent or metastatic cervical cancer who have received at least one prior systemic therapy.
Durvalumab is in development for patients with advanced/metastatic non-small cell lung cancer (NSCLC) who are EGFR/ALK wild-type and whose tumours have a high PD-L1 expression. NSCLC makes up the majority of lung cancers in the UK. Advanced/metastatic (Stage IV) NSCLC is when the cancer has spread beyond the lung which was initially affected, most often to the liver, the adrenal glands, the bones and the brain. Most patients with NSCLC are diagnosed at the advanced/metastatic stage where curative treatment with surgery is unsuitable. Currently, chemotherapy remains the first line treatment option but this is often not well tolerated by many patients.